Predicting immunotherapy response and guiding combination therapy with MOTIF
Tumor mutation burden (TMB) is considered an important predictive biomarker for the efficacy of immunotherapy. However, in cancer types where TMB is not positively correlated with the abundance of CD8+ T cells, TMB cannot ...
Mar 19, 2024
0
0